secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-05-21T21:29:34+00:00
Accession:  0001725160-26-000045
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports 39% ORR, 7.3-month median PFS for azenosertib+paclitaxel in PROC at ASCO
--------------------------------------------------------------------------------

- Phase 1b MUIR trial: all-comer PROC (n=46), ORR 39.1%, CBR 58.7%, median DOR 5.6 mo, median PFS 7.3 mo.
- At 250 mg intermittent dose (n=12): ORR 50.0%, median DOR 9.2 mo, median PFS 5.5 mo, manageable safety.
- Cyclin E1-positive (ORR 41.4%) and -negative (ORR 35.7%) patients showed comparable activity.
- Grade ≥3 TRAEs: neutropenia 30.4%, anemia 19.6%; one Grade 5 sepsis event previously reported.
- Data supports combo expansion; core focus remains azenosertib monotherapy in Cyclin E1+ PROC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000045/0001725160-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000045/zntl-20260521.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer